XBiotech has developed the anti-IL-1 alpha antibody MABp1 antibody therapies for cancer, psoriasis, acne, cardiovascular disease is in Phase III clinical trials for these biopharmaceutics for antibody therapy.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
|
FDA fast track for CRC and vascular disease mabs.
XBiotech intends to launch its first anti-infective therapy targeting methicilin resistant staphylococcus aureus (MRSA) before the end of 2014. XBiotech is also leveraging its manufacturing technology to develop ultra-low-cost biosimilar drugs. The lead molecule in this program is a "biobetter," which is expected to define a new market for the supportive care product G-CSF.